Sun Pharmaceutical

SUNPHARMA.NS

Mumbai, India· Est. 1983

sunpharma.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

SUNPHARMA.NS · Stock Price

INR 1,834.40+89.60 (+5.14%)

Market Cap: $46.9B

Historical price data

Market Cap: $46.9BPipeline: 200 drugs (61 Phase 3)Founded: 1983Employees: Over 24,000HQ: Mumbai, India

Sector Ranking#4 in Small Molecule Drugs

Overview

Sun Pharma's mission is to provide high-quality, affordable medicines globally, improving access and patient care. Its key achievement is transforming from a small startup in 1983 into a global pharmaceutical titan with a market cap exceeding $45 billion, largely through strategic acquisitions like Ranbaxy. The company's strategy is built on a dual engine: dominating the complex generics market while accelerating growth in high-margin specialty products and novel drug delivery systems across key therapeutic areas like dermatology, ophthalmology, and oncology.

NeuropsychiatryCardiovascular DiseasesGastroenterologyOncologyDermatologyOphthalmologyDiabetologyPain ManagementAnti-infectives

Technology Platform

Integrated capabilities in complex generics, novel drug delivery systems (NDDS), and biologics development, supported by vertical integration from API manufacturing to global commercialization.

Pipeline

200

200 drugs in pipeline61 in Phase 3

Drug	Indication	Stage
Ilumya Injectable Product	Psoriasis	Approved
CequaTM (Cyclosporine 0.09%) ophthalmic solution	Dry Eye Disease	Approved
Cyclosporine + Artificial tear	Dry Eye	Approved
Amifostine	Oral Mucositis	Approved
PEG-somatropin	Growth Hormone Deficiency	Approved

Funding History

IPOUndisclosedUndisclosedJun 15, 1994

FDA Approved Drugs

DEFLAZACORTANDAJan 27, 2026

DEFLAZACORTANDAMar 18, 2025

ERIBULIN MESYLATEANDAMar 4, 2025

Opportunities

Capitalizing on the global GLP-1 agonist wave with generic semaglutide, expanding specialty drug labels (e.g., ILUMYA into psoriatic arthritis), and leveraging deep penetration in high-growth emerging markets like India.

Risk Factors

Intense pricing pressure in the US generics market, regulatory compliance risks across global manufacturing network, and execution risks associated with the strategic pivot to higher-margin specialty pharmaceuticals.

Competitive Landscape

Competes with global generics giants (Teva, Sandoz) on scale and cost, and with large innovator companies (AbbVie, J&J) in specialty niches. Maintains dominant leadership in the competitive Indian domestic market against peers like Cipla and Lupin.